Trials / Terminated
TerminatedNCT05696392
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ruxolitinib cream | ruxolitinib cream 1.5% will be applied twice daily as a thin film |
Timeline
- Start date
- 2023-03-16
- Primary completion
- 2025-01-22
- Completion
- 2025-01-22
- First posted
- 2023-01-25
- Last updated
- 2025-12-19
- Results posted
- 2025-12-19
Locations
30 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05696392. Inclusion in this directory is not an endorsement.